Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS

NCT03127514 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.

NCT NCT03127514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03127514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS
Lead sponsor
Amylyx Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 22, 2017
Completion date
November 24, 2019
Enrollment
137 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, central nervous system diseases, motor neuron disease, nervous system diseases, neurodegenerative diseases, neuromuscular diseases, spinal cord diseases, tdp-43 proteinopathies